A Double blind Randomized Placebo-controlled Phase 1/2 Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Effects on Clinical Outcomes of OT-58 Administered Subcutaneously in Patients with Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
Researchers want to find out more about a study drug called OT-58 and if it may help people with homocystinuria in the future.
Description
The objective of the study is to assess the safety, tolerability, PK, PD, and preliminary efficacy of OT-58 in up to 5 dose cohorts when administered subcutaneously.
Details
| Condition | homocystinuria |
|---|---|
| Age | 12years - 65years |
| Clinical Study Identifier | TX9300 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.